News | January 23, 2024
Cipla posts Q3 FY24 consolidated PAT at Rs. 1,055.90 Cr
Cipla has reported total income of Rs. 6,788.44 crores during the period ended December 31, 2023
Cipla has reported total income of Rs. 6,788.44 crores during the period ended December 31, 2023
Produodopa is the first-and-only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of severe motor fluctuations
The PAI was conducted for two drug product applications (ANDAs) filed from this facility
The launch will enable PCC to further expand their existing Zinc Sulfate Injection product line and overall the generic injectables portfolio
Collaboration streamlines patient access to oncology clinical trials
Trastuzumab biosimilar is a humanized monoclonal antibody for treating metastatic breast cancer
The company disclosed that several employees of a subsidiary had their business email addresses stolen
The three-day event in Bengaluru was conducted in collaboration with the Karnataka Ophthalmology Society (KOS) and the Bangalore Ophthalmology Society (BOS)
Approval based on a separate phase III trial among Chinese patients reinforcing mepolizumab’s efficacy and safety data
The latest upgraded Tele Clinic is Artificial Intelligence (AI) - driven to provide healthcare facilities in far flung areas of the region, where such facilities are either not available or inadequately available
Subscribe To Our Newsletter & Stay Updated
